Do analysts rate PSTV or JUNS?

Plus Therapeutics currently has a consensus target price of $56.40, suggesting a potential upside of 1,214.69%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor PSTV or JUNS?

In the previous week, Plus Therapeutics had 1 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 4 mentions for Plus Therapeutics and 3 mentions for Jupiter Neurosciences. Plus Therapeutics' average media sentiment score of 0.97 beat Jupiter Neurosciences' score of 0.79 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JUNS or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend MRKR or JUNS?

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend JUNS or VYNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Do analysts recommend LPCN or JUNS?

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Lipocine is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer LPCN or JUNS?

In the previous week, Lipocine and Lipocine both had 3 articles in the media. Jupiter Neurosciences' average media sentiment score of 0.79 beat Lipocine's score of 0.39 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jupiter Neurosciences (JUNS) Competitors

$0.21 -0.07 (-25.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.21 0.00 (-0.95%)

As of 07:59 PM Eastern

Compare

JUNS vs. PSTV, TXMD, MRKR, VYNE, and LPCN

Should you buy Jupiter Neurosciences stock or one of its competitors? MarketBeat compares Jupiter Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jupiter Neurosciences include Plus Therapeutics (PSTV), TherapeuticsMD (TXMD), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), and Lipocine (LPCN). These companies are all part of the "med - drugs" industry.

How does Jupiter Neurosciences compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Jupiter Neurosciences has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Jupiter Neurosciences has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.67	-$22.39M	-$2.30	N/A
Jupiter Neurosciences	$20K	380.94	-$8.65M	-$0.27	N/A

Plus Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market.

In the previous week, Plus Therapeutics had 1 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 4 mentions for Plus Therapeutics and 3 mentions for Jupiter Neurosciences. Plus Therapeutics' average media sentiment score of 0.97 beat Jupiter Neurosciences' score of 0.79 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jupiter Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.3% of Plus Therapeutics shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Plus Therapeutics currently has a consensus target price of $56.40, suggesting a potential upside of 1,214.69%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Plus Therapeutics is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Plus Therapeutics beats Jupiter Neurosciences on 9 of the 16 factors compared between the two stocks.

How does Jupiter Neurosciences compare to TherapeuticsMD?

Jupiter Neurosciences (NASDAQ:JUNS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Jupiter Neurosciences has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of 5.34% compared to Jupiter Neurosciences' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
TherapeuticsMD	5.34%	0.32%	0.23%

30.7% of TherapeuticsMD shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Jupiter Neurosciences had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Jupiter Neurosciences' score of 0.79 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
TherapeuticsMD	Very Positive

TherapeuticsMD has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	380.94	-$8.65M	-$0.27	N/A
TherapeuticsMD	$3.02M	8.58	-$570K	$0.06	37.33

Summary

TherapeuticsMD beats Jupiter Neurosciences on 9 of the 13 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

22.4% of Marker Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Jupiter Neurosciences has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.61	N/A
Jupiter Neurosciences	$20K	380.94	-$8.65M	-$0.27	N/A

Marker Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

In the previous week, Jupiter Neurosciences had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.96 beat Jupiter Neurosciences' score of 0.79 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Positive
Jupiter Neurosciences	Positive

Summary

Marker Therapeutics and Jupiter Neurosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Jupiter Neurosciences (NASDAQ:JUNS) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Jupiter Neurosciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Jupiter Neurosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

83.8% of VYNE Therapeutics shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Jupiter Neurosciences had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat Jupiter Neurosciences' score of 0.79 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
VYNE Therapeutics	Very Positive

Jupiter Neurosciences has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	380.94	-$8.65M	-$0.27	N/A
VYNE Therapeutics	$454K	47.57	-$26.48M	-$0.38	N/A

Summary

Jupiter Neurosciences and VYNE Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Jupiter Neurosciences has lower revenue, but higher earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A
Jupiter Neurosciences	$20K	380.94	-$8.65M	-$0.27	N/A

9.1% of Lipocine shares are owned by institutional investors. 6.4% of Lipocine shares are owned by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Jupiter Neurosciences has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

In the previous week, Lipocine and Lipocine both had 3 articles in the media. Jupiter Neurosciences' average media sentiment score of 0.79 beat Lipocine's score of 0.39 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market.

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Lipocine is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jupiter Neurosciences beats Lipocine on 8 of the 15 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.16M	$3.04B	$6.85B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.78	19.67	26.04	24.36
Price / Sales	380.94	349.52	550.17	103.06
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	-4.20	4.25	10.98	6.49
Net Income	-$8.65M	$64.45M	$3.57B	$336.61M
7 Day Performance	-8.70%	4.17%	3.06%	0.90%
1 Month Performance	-17.97%	1.44%	0.72%	-0.36%
1 Year Performance	-80.00%	34.07%	36.82%	31.26%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JUNS Jupiter Neurosciences	0.9207 of 5 stars	$0.21 -25.0%	N/A	-73.0%	$10.16M	$20K	N/A	5	Short Interest Decrease Gap Down
PSTV Plus Therapeutics	2.6704 of 5 stars	$3.96 -2.9%	$56.40 +1,324.2%	-46.7%	$28.09M	$5.21M	N/A	20
TXMD TherapeuticsMD	1.6933 of 5 stars	$2.01 +0.5%	N/A	+88.4%	$23.15M	$3.02M	33.50	420
MRKR Marker Therapeutics	2.2341 of 5 stars	$1.31 -4.4%	$10.00 +663.4%	-9.9%	$22.84M	$3.55M	N/A	60
VYNE VYNE Therapeutics	1.4775 of 5 stars	$0.65 +0.1%	N/A	-54.3%	$21.68M	$570K	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. PSTV, TXMD, MRKR, VYNE, and LPCN

How does Jupiter Neurosciences compare to Plus Therapeutics?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Summary

How does Jupiter Neurosciences compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. PSTV, TXMD, MRKR, VYNE, and LPCN

How does Jupiter Neurosciences compare to Plus Therapeutics?

Is PSTV or JUNS more profitable?

Which has preferable valuation & earnings, PSTV or JUNS?

Which has more volatility & risk, PSTV or JUNS?

Does the media favor PSTV or JUNS?

Do institutionals and insiders hold more shares of PSTV or JUNS?

Do analysts rate PSTV or JUNS?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Which has more volatility & risk, JUNS or TXMD?

Do analysts prefer JUNS or TXMD?

Is JUNS or TXMD more profitable?

Do insiders and institutionals hold more shares of JUNS or TXMD?

Does the media refer more to JUNS or TXMD?

Which has better earnings & valuation, JUNS or TXMD?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Do insiders & institutionals hold more shares of MRKR or JUNS?

Do analysts recommend MRKR or JUNS?

Is MRKR or JUNS more profitable?

Which has better valuation and earnings, MRKR or JUNS?

Which has more risk & volatility, MRKR or JUNS?

Does the media refer more to MRKR or JUNS?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Do analysts recommend JUNS or VYNE?

Which has more volatility & risk, JUNS or VYNE?

Is JUNS or VYNE more profitable?

Do institutionals and insiders believe in JUNS or VYNE?

Does the media refer more to JUNS or VYNE?

Which has higher earnings and valuation, JUNS or VYNE?

Summary

How does Jupiter Neurosciences compare to Lipocine?

Which has better earnings and valuation, LPCN or JUNS?

Do institutionals & insiders believe in LPCN or JUNS?

Is LPCN or JUNS more profitable?

Does the media prefer LPCN or JUNS?

Which has more volatility and risk, LPCN or JUNS?

Do analysts recommend LPCN or JUNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools